2023 World Conference on Lung Cancer (Posters)-EP12.01. Efficacy of Amivantamab in a Patient with EGFR ex20ins Lung Adenocarcinoma with Symptomatic Pleural Effusion after Platinum Doublet Failure

EP12.01. Efficacy of Amivantamab in a Patient with EGFR ex20ins Lung Adenocarcinoma with Symptomatic Pleural Effusion after Platinum Doublet Failure - PDF(Abstract)

Back to course

Pdf Summary

This case report presented at the WCLC 2023 conference discusses the efficacy of amivantamab in a patient with EGFR exon 20 insertion (Ex20ins) lung adenocarcinoma who had symptomatic pleural effusion after platinum doublet failure. The patient, a 63-year-old female, was initially diagnosed with stage IVA NSCLC with EGFR Ex20ins and experienced dyspnea and right-sided pain. CT scans revealed a right mass and pleural effusion, and biopsy confirmed lung adenocarcinoma. The patient underwent palliative chemotherapy with carboplatin and pemetrexed, achieving stable disease as the best response. However, after two cycles, the patient's symptoms worsened, with increased pleural effusion and mass. Compassionate use of amivantamab was granted, and the patient experienced fast improvement in symptoms. The first CT scan after amivantamab treatment showed a partial response, which has persisted for four months. The patient experienced mild toxicity, including paronychia, rash, and mucositis, which were easily managed. No infusional reactions were observed with the use of prophylactic measures. This case highlights the benefit of amivantamab in patients with NSCLC EGFR Ex20ins, a subset that has traditionally been challenging to treat with conventional chemotherapy or classical target therapies. The report suggests that amivantamab may also have activity against symptomatic pleural effusion in this population. This study provides valuable insights into the potential of targeted therapy with amivantamab for patients with EGFR Ex20ins lung adenocarcinoma.

Asset Subtitle

Javier Baena

Meta Tag

Speaker Javier Baena

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

WCLC 2023 conference

amivantamab efficacy

EGFR exon 20 insertion

lung adenocarcinoma

symptomatic pleural effusion

platinum doublet failure

NSCLC

carboplatin and pemetrexed

partial response

targeted therapy